Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Ownership & Trading Activity
Institutional holders, insider transactions, and congressional trades for ARQT. 13F holdings as of 2026-09-30.
In 13F filings for the quarter ended September 30, 2026, 208 institutions reported holding ARQT, with 78.8 million shares worth $2.1 billion in aggregate.
Top Institutional Holders
| Institution | Shares | Value | Change |
|---|---|---|---|
| BlackRock | 19,171,035 | $507M | INCREASED |
| Vanguard | 9,796,992 | $259M | INCREASED |
| State Street | 7,718,628 | $204M | INCREASED |
| UBS Group | 5,533,053 | $146M | INCREASED |
| Morgan Stanley | 5,296,532 | $140M | INCREASED |
Recent Insider Trades
| Insider | Type | Shares | Value | Date |
|---|---|---|---|---|
| Masaru Matsuda (EVP, Chief Legal Officer) | EXERCISE | 40,000 | $146K | 2026-11-04 |
| Masaru Matsuda (EVP, Chief Legal Officer) | SELL | 40,000 | $1M | 2026-11-04 |
| Masaru Matsuda (EVP, Chief Legal Officer) | EXERCISE | 40,000 | $146K | 2026-11-04 |
| Todd Watanabe (Reporting Person's title: President and Chief Executive Officer) | SELL | 4,377 | $139K | 2026-11-02 |
| Patrick Burnett (EVP, Chief Medical Officer) | SELL | 943 | $30K | 2026-11-02 |
Full institutional holdings, insider history, and congressional trades for Arcutis Biotherapeutics, Inc. Common Stock on SentiSense.